FGF19 and metabolic dysfunction-associated steatohepatitis: The expression of FGF19's corresponding receptor FGFR4 showed statistically significant increases in specimens with ST (539.88 ± 258.37, p = 0.004), NASH (1142.52 ± 397.49, p = 0.0004), CR (974.96 ± 170.25, p < 0.0001) and HCC (2099.32 ± 594.80, p < 0.0001) as compared with the paired peritumoral tissues (156.27 ± 47.57).